Slingshot members are tracking this event:
Agios Pharma (AGIO) to report data from Phase 1 study of AG-519 in patients with PK deficiency in at European Hematology Association Meeting
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -- Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Levels Observed Consistent with PKR Enzyme Activation -
Slingshot Insights Explained
Jun 20, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Interim Data, Phase 1 Data, Ag-519, Pyruvate Kinase Deficiency, Pk Deficiency, European Hematology Association, Double Blind